# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SCHEDULE 13G (Rule 13d-102)

# INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (b) (Amendment No. 2)

AC IMMUNE SA (Name of Issuer)

Common shares, nominal value CHF 0.02 per share (Title of Class of Securities)

H00263105 (CUSIP Number)

December 31, 2018 (Date of Event Which Requires Filing of This Statement)

Check tl	he appropriate box to designate the rule pursuant to which this Schedule is filed:
	Rule 13d-1(b)
	Rule 13d-1(c)
$\boxtimes$	Rule 13d-1(d)
	emainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, equent amendment containing information which would alter disclosures provided in a prior cover page.
	ormation required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however,

CUSIP NO.	CUSIP NO. H00263105			13 G	Page 2 of 14 Pages	
1.	Name of Rep	Name of Reporting Persons				
	dievini Hopp	ВіоТес	h holding GmbH & Co. K	G.G		
2.			e Box if a Member of a Gro			
	(a) □ (b	) 🗆 (1)				
3.	SEC USE ON	,				
4.	Citizenship o	r Place o	f Organization			
	Germany					
		5.	Sole Voting Power			
Numb	er of		0 common shares			
Shar		6.	Shared Voting Power			
Benefic Owne			18,041,000 common sha	ares (2)		
Eac		7.	Sole Dispositive Power			
Repor Pers			0 common shares			
Wit		8.	Shared Dispositive Pow	ver		
			18,041,000 common sha			
9.	Aggregate Amount Beneficially Owned by Each Reporting Person					
	18,041,000 common shares <sup>(2)</sup>					
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □					
11.	Percent of Class Represented by Amount in Row (9)					
12.	26.7% <sup>(3)</sup> Type of Reporting Person (See Instructions)					
14.	Type of Kepo	nung rei	son (See manuchons)			
	00					

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents shares held of record by dievini.
- (3) This percentage is calculated based on 67,562,333 shares of the Issuer's common shares reported to be issued by the Issuer in its Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 21, 2019.

CUSIP NO.	D. H00263105			13 G	Page 3 of 14 Pages		
1.	Name of 1	Name of Reporting Persons					
	DH-Cani	tal GmbH 8	B Co KG				
2.			e Box if a Member of a Gro	oup (See Instructions)			
	(a) □	(b) □ <sup>(1)</sup>					
3.	SEC USE	ONLY					
4.	Citizanchi	in or Dlace o	f Organization				
4.	Citizensiii	ip of Flace o	i Organizacion				
	Germany						
		5.	Sole Voting Power				
			0 common shares				
Numb Shar		6.	Shared Voting Power				
Benefic							
Owne			18,041,000 common sha				
Eac		7.	Sole Dispositive Power				
Repor Pers			0 common shares				
Wit		8.	Shared Dispositive Pow	ver			
		0.	Sharea Dispositive Fow	Ci .			
	=		18,041,000 common sha				
9.	Aggregate	e Amount B	eneficially Owned by Each	Reporting Person			
10.	18,041,000 common shares <sup>(2)</sup> Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □				uctions)		
10.	Check if the Aggregate Aniount in Now (9) Excludes Certain Shales (See histractions)						
11.	Percent of Class Represented by Amount in Row (9)						
10	26.7% <sup>(3)</sup> Type of Reporting Person (See Instructions)						
12.	Type of R	ерогипд Реі	son (see instructions)				
	00						

- This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- Represents shares held of record by dievini.
- This percentage is calculated based on 67,562,333 shares of the Issuer's common shares reported to be issued by the Issuer in its Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 21, 2019.

CUSIP NO.	H0020310	JJ	Page 4 of 14 Pages				
			<u> </u>				
1.	Name of	Name of Reporting Persons					
			mbH & Co. KG				
2.	Check th	ne Appropriat	e Box if a Member of a Group (See Instructions)				
	(a) 🗆	(b) □ <sup>(1)</sup>					
3.	SEC US	E ONLY					
4.	Citizens	hip or Place o	f Organization				
	German	у					
		5.	Sole Voting Power				
Numbe	er of		0 common shares				
Shar		6.	Shared Voting Power				
Benefic							
Owned Eac		7	18,041,000 common shares <sup>(2)</sup>				
Repor		7.	Sole Dispositive Power				
	Person 0 common shares						
With	h:	8.	Shared Dispositive Power				
	18,041,000 common shares <sup>(2)</sup>						
9.	Aggrega	te Amount Be	eneficially Owned by Each Reporting Person				
	18,041,000 common shares <sup>(2)</sup>						
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □						
11.	Percent of Class Represented by Amount in Row (9)						
10		26.7% <sup>(3)</sup> Type of Reporting Person (See Instructions)					
12.	Type of	keporting Pei	son (See Instructions)				
	00						
-							

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents shares held of record by dievini.
- (3) This percentage is calculated based on 67,562,333 shares of the Issuer's common shares reported to be issued by the Issuer in its Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 21, 2019.

CUSIP NO.	JSIP NO. H00263105			13 G	Page 5 of 14 Pages	
1.	Name of R	Name of Reporting Persons				
	Dietmar H	Іорр				
2.			e Box if a Member of a Gro	oup (See Instructions)		
	_	<b>—</b> (1)				
3.	(a) □ SEC USE	(b) (1)				
3.	SEC USE	UNLY				
4.	Citizenshij	or Place o	of Organization			
	Germany					
	Germany	5.	Sole Voting Power			
Numbe	er of		0 common shares			
Shar		6.	Shared Voting Power			
Benefic Owne			18,041,000 common sha	ares (2)		
Eac		7.	Sole Dispositive Power			
Repor						
Pers Wit		0	0 common shares			
***************************************		8.	Shared Dispositive Pow	7er		
			18,041,000 common sha	ares <sup>(2)</sup>		
9.	Aggregate	Amount B	eneficially Owned by Each	Reporting Person		
	18,041,000 common shares <sup>(2)</sup>					
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □				actions) 🗆	
11.	1. Percent of Class Represented by Amount in Row (9)					
	26.7% <sup>(3)</sup>					
12.	Type of Reporting Person (See Instructions)					
		-	·			
	IN					

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents shares held of record by dievini.
- (3) This percentage is calculated based on 67,562,333 shares of the Issuer's common shares reported to be issued by the Issuer in its Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 21, 2019.

	00263105		13 G	Page 6 of 14 Pages	
1.	Name of Reporting	Persons			
	OP II				
	Oliver Hopp	ate Box if a Member of a Gro	(Co. Instructions)		
2.	Спеск тве Арргоргі	ate Box if a Member of a Gro	oup (See Instructions)		
	(a) $\Box$ (b) $\Box$ (1	)			
	SEC USE ONLY				
4.	Citizenship or Place	of Organization			
	Germany				
	5.	Sole Voting Power			
	5.	Sole voiling I ower			
Number (	of	0 common shares			
Shares		Shared Voting Power			
Beneficial	lly				
Owned b		18,041,000 common sh			
Each	7.	Sole Dispositive Power			
Reportin Person		0			
With:	8.	0 common shares Shared Dispositive Pow	zon.		
	0.	Shared Dispositive Fow	vei		
		18,041,000 common sh	ares <sup>(2)</sup>		
9. <i>I</i>	Aggregate Amount	Beneficially Owned by Each			
		(0)			
	18,041,000 common shares <sup>(2)</sup>				
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) $\square$				
11. I	Percent of Class Represented by Amount in Row (9)				
	26.7% <sup>(3)</sup>				
12.	Type of Reporting P	erson (See Instructions)			
	TNI				
1	IN				

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents shares held of record by dievini.
- (3) This percentage is calculated based on 67,562,333 shares of the Issuer's common shares reported to be issued by the Issuer in its Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 21, 2019.

CUSIP NO.	USIP NO. H00263105			13 G	Page 7 of 14 Pages	
				·		
1.	Name of R	Name of Reporting Persons				
	Daniel Ho	nn				
2.			e Box if a Member of a Gro	oup (See Instructions)		
		41				
		(b) (1)				
3.	SEC USE	ONLY				
4.	Citizenshij	or Place o	f Organization			
	Germany					
		5.	Sole Voting Power			
Numb		6.	0 common shares			
Shar		о.	Shared Voting Power			
Benefic Owne			18,041,000 common sha	ares <sup>(2)</sup>		
Eac	ch .	7.	Sole Dispositive Power			
Repor						
Pers Wit		8.	0 common shares Shared Dispositive Pow	TOP.		
,,,,,		0.	Shared Dispositive Pow	/ei		
			18,041,000 common sha	ares <sup>(2)</sup>		
9.	Aggregate	Amount Bo	eneficially Owned by Each	Reporting Person		
	18,041,000 common shares <sup>(2)</sup>					
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)				actions) 🗆	
11.	Percent of Class Represented by Amount in Row (9)					
	26.7% <sup>(3)</sup>					
12.	Type of Reporting Person (See Instructions)					
	INI					
	IN					
	<del>-</del>					

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents shares held of record by dievini.
- (3) This percentage is calculated based on 67,562,333 shares of the Issuer's common shares reported to be issued by the Issuer in its Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 21, 2019.

CUSIP NO. H00263105				13 G	Page 8 of 14 Pages
1.	Name of	Reporting Pe	ersons		
	Dwof Da	. Eviodvich v	on Bohlen und Halbach		
2.			e Box if a Member of a Gro	un (See Instructions)	
۷.	Check ti	ic rippropriat	e box if a Weinber of a Gro	up (occ instructions)	
	(a) 🗆	(b) □ <sup>(1)</sup>			
3.	SEC US	E ONLY			
4.	Citizens	hip or Place o	f Organization		
	German	v			
		5.	Sole Voting Power		
Numb	er of		11,828 common shares <sup>(2</sup>	2)	
Shar		6.	Shared Voting Power		
Benefic			18,041,000 common sha	<sub>2000</sub> (3)	
Owne Eac		7.	Sole Dispositive Power	ares.	
Repor		<b>/·</b>	Sole Dispositive I owel		
Pers	on		11,828 common shares <sup>(2</sup>	2)	
Wit	h:	8.	Shared Dispositive Pow	er	
				(2)	
			18,041,000 common sha		
9.	Aggrega	ite Amount Be	eneficially Owned by Each	Reporting Person	
	18.052.8	328 common s	shares <sup>(4)</sup>		
10.				ıdes Certain Shares (See Instruct	ions) 🗆
11.	Percent	of Class Repr	esented by Amount in Row	(9)	
	22.75)				
12.	26.7% <sup>(5)</sup> Type of Reporting Person (See Instructions)				
12.	Type of	rehorning bei	son (see msuuchons)		
	IN				

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- Represents shares held of record directly by Dr. von Bohlen.
- Represents shares held of record by dievini

CUSIP NO. H00263105

- Represents 18,041,000 shares held of record by divieni and 11,828 shares held directly by Dr. von Bohlen.
- This percentage is calculated based on 67,562,333 shares of the Issuer's common shares reported to be issued by the Issuer in its Annual Report on (5) Form 20-F filed with the Securities and Exchange Commission on March 21, 2019.

CUSIP NO. H00263105				13 G	Page 9 of 14 Pages
1.	Name of	f Reporting Pe	ersons		
	Dwof D	r. Christof He	attich		
2.			e Box if a Member of a Gro	up (Soo Instructions)	
۷.	Clieck ti	не Арргориан	e Dox ii a Meilibei oi a Gio	up (See mstructions)	
	(a) 🗆	(b) $\Box$ (1)			
3.		SE ONLY			
4.	Citizens	hip or Place o	f Organization		
	German	y			
		5.	Sole Voting Power		
Numbe	er of		174,750 common shares	<sub>S</sub> (2)	
Shar		6.	Shared Voting Power		
Benefic			18,041,000 common sha	(3)	
Owned Eac		7.	Sole Dispositive Power	ares (=)	
Repor		/.	Sole Dispositive Fower		
Pers	on		174,750 common shares	<sub>S</sub> (2)	
Wit	n:	8.	Shared Dispositive Pow	er	
			18,041,000 common sha		
9.	Aggrega	ate Amount Be	eneficially Owned by Each	Reporting Person	
	10 215 5	7E0 comme	shaves (4)		
10.	18,215,750 common shares <sup>(4)</sup> Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □				
10.	Check if the Aggregate Amount in Row (9) excludes Certain Shares (See Instructions)				
11.	Percent of Class Represented by Amount in Row (9)				
	27.0% <sup>(5)</sup>				
12.	Type of	Reporting Per	rson (See Instructions)		
	IN				
	211				

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- Represents shares held directly by Dr. Hettich through his personal accounts, of which he has sole voting and dispositive power.
- Represents shares held of record by dievini.

CUSIP NO. H00263105

- Includes (i) 174,750 common shares held directly by Dr. Hettich, of which he has sole voting and dispositive power and (ii) 18,041,000 common shares held of record by dievini, of which Dr. Hettich shares voting and dispositive power as a managing director of dievini.
- This percentage is calculated based on 67,562,333 shares of the Issuer's common shares reported to be issued by the Issuer in its Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 21, 2019.

		_	1 4 5 1 0 1 1 1 4 6 5			
1.	Name of	Reporting Pe	ersons			
		hias Hothum				
2.	Check th	e Appropriate	e Box if a Member of a Group (See Instructions)			
		- (1)				
_	(a) □	(b) $\Box$ (1)				
3.	SEC US	E ONLY				
4.	Citizanel	nin or Dlace o	f Organization			
٦.	Citizensi	iip or r face o	1 Organization			
	Germany	7				
		5.	Sole Voting Power			
Numbe	er of		36,500 common shares <sup>(2)</sup>			
Shar		6.	Shared Voting Power			
Benefic			(3)			
Owned Eac			18,041,000 common shares <sup>(3)</sup>			
Repor		7.	Sole Dispositive Power			
Perso			36,500 common shares <sup>(2)</sup>			
Wit		8.	Shared Dispositive Power			
		0.	Shared Dispositive Forces			
			18,041,000 common shares <sup>(3)</sup>			
9.	Aggrega	te Amount Be	eneficially Owned by Each Reporting Person			
	18,077,500 common shares <sup>(4)</sup>					
10.	Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) $\Box$					
11.	Percent of Class Represented by Amount in Row (9)					
11.	1 ercent of Class Represented by Amount in Row (3)					
	26.8 <sup>(5)</sup>					
12.	Type of Reporting Person (See Instructions)					
		- 0				
	IN					

Page 10 of 14 Pages

- (1) This Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH& Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons"). The Reporting Persons expressly disclaim status as a "group" for purposes of this Schedule 13G.
- (2) Represents shares held directly by Dr. Hothum through his personal accounts, of which he has sole voting and dispositive power.
- (3) Represents shares held of record by dievini.

CUSIP NO H00263105

- (4) Includes (i) 36,500 common shares held directly by Dr. Hothum, of which he has sole voting and dispositive power and (ii) 18,041,000 common shares held of record by dievini, of which Dr. Hothum shares voting and dispositive power as a managing director of dievini.
- (5) This percentage is calculated based on 67,562,333 shares of the Issuer's common shares reported to be issued by the Issuer in its Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 21, 2019.

CUSIP NO. H00263105	13 G	Page 11 of 14 Pages
---------------------	------	---------------------

Introductory Note: This Amendment No. 1 to Schedule 13G is filed by dievini Hopp BioTech holding GmbH & Co. KG ("dievini"), DH-Capital GmbH & Co. KG ("DH-Capital"), OH Beteiligungen GmbH & Co. KG ("OH Beteiligungen"), Dietmar Hopp, Oliver Hopp, Daniel Hopp, Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen"), Prof. Dr. Christof Hettich ("Dr. Hettich"), Dr. Mathias Hothum ("Dr. Hothum" and together with dievini, DH-Capital, OH Beteiligungen, Dietmar Hopp, Oliver Hopp, Daniel Hopp, Dr. von Bohlen and Dr. Hettich, collectively, the "Reporting Persons") in respect of common shares of AC Immune SA.

### Item 1(a) Name of Issuer:

AC Immune SA

### Item 1(b) Address of Issuer's principal executive offices:

EPFL Innovation Park Building B 1015 Lausanne Switzerland

### Items 2(a) Name of Reporting Persons filing:

dievini Hopp BioTech holding GmbH & Co. KG ("dievini") DH-Capital GmbH & Co. KG ("DH-Capital") OH Beteiligungen GmbH & Co. KG ("OH Beteiligungen") Dietmar Hopp Oliver Hopp Daniel Hopp Prof. Dr. Friedrich von Bohlen und Halbach ("Dr. von Bohlen") Prof. Dr. Christof Hettich ("Dr. Hettich") Dr. Mathias Hothum ("Dr. Hothum")

### Item 2(b) Address or principal business office or, if none, residence:

The address of the principal business office of dievini, Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum is c/o dievini Hopp BioTech holding GmbH & Co. KG, Johann-Jakob-Astor Straße 57, 69190 Walldorf, Germany.

The address of the principal business office of DH-Capital GmbH & Co. KG and OH Beteiligungen GmbH & Co. KG is Heidelberger Straße 43, 69168 Wiesloch, Germany.

The address of the principal business office of Oliver Hopp is Johann-Jakob-Astor-Straße 59, 69190 Walldorf, Germany.

The address of the principal business office of Daniel Hopp is Johann-Jakob-Astor-Straße 57, 69190 Walldorf, Germany.

### Item 2(c) Citizenship:

Name	Citizenship or Place of Organization
Dievini	Germany
DH-Capital	Germany
OH Beteiligungen	Germany
Dietmar Hopp	Germany
Oliver Hopp	Germany
Daniel Hopp	Germany
Dr. von Bohlen	Germany
Dr. Hettich	Germany
Dr. Hothum	Germany

### Item 2(d) Title of class of securities:

Common shares, nominal value CHF 0.02 per share

### Item 2(e) CUSIP No.:

H00263105

Item 3 If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filings is a:

Not applicable.

### Item 4 Ownership

The following information with respect to the ownership of common shares of the Issuer by the Reporting Persons filing this statement on Schedule 13G is provided as of December 31, 2018.

Reporting Persons	Common Shares Held Directly	Sole Voting Power	Shared Voting Power	Sole Dispositive Power	Shared Dispositive Power	Beneficial Ownership	Percentage of Class <sup>(1)</sup>
dievini Hopp BioTech holding GmbH & Co.	Directly	Tower	Tower	Tower	Tower	Ownership	Ciuss
KG <sup>(2)</sup>	18,041,000	0	18,041,000	0	18,041,000	18,041,000	26.7%
DH-Capital GmbH & Co. KG <sup>(3)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	26.7%
OH Beteiligungen GmbH & Co. KG <sup>(3)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	26.7%
Dietmar Hopp <sup>(3)(4)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	26.7%
Oliver Hopp <sup>(3)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	26.7%
Daniel Hopp <sup>(5)</sup>	0	0	18,041,000	0	18,041,000	18,041,000	26.7%
Prof. Dr. Friedrich von Bohlen und Halbach <sup>(3)(4)</sup>	11,828	11,828	18,041,000	11,828	18,041,000	18,052,828	26.7%
Prof. Dr. Christof Hettich <sup>(3)(4)</sup>	174,750(6)	174,750	18,041,000	174,750	18,041,000	18,215,750	27.0%
Dr. Mathias Hothum <sup>(4)</sup>	36,500(7)	36,500	18,041,000	36,500	18,041,000	18,077,500	26.8%

- (1) This percentage is calculated based on 67,562,333 shares of the Issuer's common shares reported to be issued by the Issuer in its Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 21, 2019.
- (2) 18,041,000 common shares of the Issuer are held of record by dievini.
- (3) DH-Capital, OH Beteiligungen, Dr. von Bohlen and Dr. Hettich are collectively the holders of 100% of the limited partner interest in dievini. DH-Capital and OH Beteiligungen each hold a 40% limited partner interest in dievini and therefore, control the voting and dispositive decisions of dievini together and may be deemed to beneficially own the shares held by dievini. Dietmar Hopp and Oliver Hopp are the ultimate controlling persons of dievini, DH-Capital and OH Beteiligungen, and control the voting and investment decisions of the ultimate parent company of dievini and therefore, may be deemed to beneficially own the shares held by dievini by virtue of their status as controlling persons of dievini.
- (4) The sole general partner of dievini with the authorization to represent is dievini Verwaltungs GmbH; however, 100% of the shares of dievini Verwaltungs GmbH are held by dievini so dievini Verwaltungs GmbH is not considered to have control over dievini. The managing directors of dievini Verwaltungs GmbH are Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum. Voting and dispositive decisions made within dievini Verwaltungs GmbH regarding the securities held by dievini are made by at least two managing directors acting together; however, Dietmar Hopp is entitled to represent dievini Verwaltungs GmbH solely. Therefore, in their capacity as managing directors, Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum share voting and dispositive power over the shares held by dievini, and may be deemed to beneficially own such shares held by dievini; however, each of Dietmar Hopp, Dr. von Bohlen, Dr. Hettich and Dr. Hothum disclaims beneficial ownership of the shares held by dievini except to the extent of their pecuniary interests therein.
- (5) Daniel Hopp has shared control of DH-Capital and he may therefore be deemed to beneficially own the shares held by dievini; however, Daniel Hopp disclaims beneficial ownership of the shares held by dievini except to the extent of his pecuniary interests therein.
- (6) Represents shares held through personal accounts, of which the holder has sole voting and dispositive power.
- (7) Represents shares held directly by Dr. Hothum through his personal accounts, of which he has sole voting and dispositive power.

CLICID N	IO. H00263105	13 G	Page 13 of 14 Pages				
CUSIP N	NO. H00203103	13 G	Page 13 01 14 Pages				
Item 5	Ownership of Five Percent or Less of a Class						
	If this statement is being filed to report the fact that as of the date hereof, the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: $\Box$						
Item 6	Ownership of More than Five Percent on Behalf of Another Person						
	Not applicable.						
Item 7	Identification and Classification of the Subsidiary or Control Person	Which Acquired the	Security Being Reported on by the Parent Holding Company				
	Not applicable.						
Item 8	Identification and Classification of Members of th	ne Group					
	Not applicable.						
Item 9	Notice of Dissolution of Group						
	Not applicable.						
Item 10	Certifications						
	Not applicable.						

CUSIP NO. H00263105 13 G Page 14 of 14 Pages

### **SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 6, 2020

## DIEVINI HOPP BIOTECH HOLDING GMBH & CO. KG

By: dievini Verwaltungs GmbH

its General Partner

By: /s/ Dr. Marc Hauser

Name: Dr. Marc Hauser Title: Attorney-in-fact

### DH-CAPITAL GMBH & CO. KG

By: DH Verwaltungs GmbH its General Partner

By: /s/ Dr. Marc Hauser

Name: Dr. Marc Hauser Title: Attorney-in-fact

### OH BETEILIGUNGEN GMBH & CO. KG

By: OH Verwaltungs GmbH its General Partner

By: /s/ Dr. Marc Hauser

Name: Dr. Marc Hauser Title: Attorney-in-fact

/s/ Dr. Marc Hauser as attorney-in-fact

### **DIETMAR HOPP**

/s/ Dr. Marc Hauser as attorney-in-fact

### **OLIVER HOPP**

/s/ Dr. Marc Hauser as attorney-in-fact

### **DANIEL HOPP**

/s/ Dr. Marc Hauser as attorney-in-fact

## FRIEDRICH VON BOHLEN UND HALBACH

/s/ Dr. Marc Hauser as attorney-in-fact

## CHRISTOF HETTICH

/s/ Dr. Marc Hauser as attorney-in-fact

### MATHIAS HOTHUM

### Exhibit(s):

1 – Power of Attorney Incorporated by reference to Exhibit 99.1 to the Schedule 13G filed by the Reporting Persons on February 14, 2017 with respect to the common shares of the Issuer.

2 - Joint Filing Statement Incorporated by reference to Exhibit 99.2 to the Schedule 13G filed by the Reporting Persons on February 14, 2017 with respect to the common shares of the Issuer.